ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pediatric rheumatology"

  • Abstract Number: 1739 • ACR Convergence 2024

    Adult and Pediatric Rheumatology Fellow Education on Temporomandibular Joint (TMJ) Arthritis in Patients with Juvenile Idiopathic Arthritis

    Sarah Bayefsky1, Meghan Ryan2, Nancy Pan3, Tova Ronis4, Marinka Twilt5, Melissa Lerman6 and CARRA TMJ Workgroup7, 1University of Pennsylvania/Children's Hospital of Philadelphia, PHILADELPHIA, PA, 2Unity Point - Blank Children's Hospital, Booneville, IA, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Children's National Hospital, Washington, DC, 5Alberta Children's Hospital, Calgary, AB, Canada, 6Children's Hospital of Philadelphia, Philadelphia, PA, 7CARRA, Washington, DC

    Background/Purpose: Arthritis of the temporomandibular joint, or TMJ arthritis, is an underrecognized manifestation of juvenile idiopathic arthritis (JIA). The absence of prompt treatment may lead…
  • Abstract Number: 1792 • ACR Convergence 2024

    CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus

    Lauren Robinson1, Preetha Balasubramanian2, Zurong Wan2, Juan Rodriguez Alcazar2, Marina Lima Silva Santos2, Lynnette Walters3, Jeanine Baisch2, Karen Onel4, Tracey Wright5, Virginia Pascual6 and Simone Caielli2, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Scottish Rite Hospital for Children, Allen, TX, 4HSS, New York, NY, 5UT Southwestern, Plano, TX, 6Weill Cornell Medical College, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
  • Abstract Number: 2176 • ACR Convergence 2024

    Applying Similarity Network Fusion to Identify Patient Clusters for People with Systemic Inflammatory Disease

    Nicholas C Chan1, Anika Rueppell2, Daniela Dominguez3, Tom Appleton4, Michelle Batthish5, Roberta A Berard6, Tania Cellucci5, Erkan Demirkaya7, Michelle Diebold6, Liane Heale8, Peter Kannu9, Deborah Levy10, Jonathan Park11, Jean-Philippe Proulx-Gauthier12, Angela Punnett10, Johannes Roth13, Rayfel Schneider14, Lynn Spiegel15, Rae Yeung16, Jason An1, Anjali Jain3, Madeline Couse10, Dilan Dissanayake10, Ronald Laxer2, Lauren Erdman10 and Linda Hiraki10, 1University of Toronto, Toronto, ON, Canada, 2SickKids, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, Canada, 4The University of Western Ontario, London, ON, Canada, 5McMaster Children's Hospital, Hamilton, ON, Canada, 6London Health Sciences Centre, London, ON, Canada, 7Victoria Hospital & Children's Hospital, Toronto, ON, Canada, 8McMaster University, Oakville, ON, Canada, 9University of Alberta, Edmonton, AB, Canada, 10The Hospital for Sick Children, Toronto, ON, Canada, 11London Health Sciences Centre Victoria Hospital, Lodon, Canada, 12l'Université Laval, Quebec City, QC, Canada, 13Cantonal Hospital Luzern and Children's Hospital of Central Switzerland, Luzern, Switzerland, 14The Hospital for Sick Children, Toronto, Ontario, Canada, Toronto, ON, Canada, 15University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, 16The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic inflammatory diseases (SIDs) are characterized by non-infectious multisystem inflammation. Genetic panels only diagnose 25% of suspected SID patients, due to the clinical and…
  • Abstract Number: 2200 • ACR Convergence 2024

    Whole Blood Transcriptome Profiling in Juvenile Systemic Sclerosis Patients Reveals Active Immune Upregulation and Enhanced Fibrotic Signature

    Rania Elbakri1, Amanda Robinson2, Anwesha Sanyal1 and Kathryn Torok3, 1University of Pittsburgh, pittsburgh, PA, 2University of Utah Health, Salt Lake City, UT, 3Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare chronic autoimmune disorder characterized by skin thickening and multisystem organ involvement, leading to significant morbidity. The pathogenesis…
  • Abstract Number: 2570 • ACR Convergence 2024

    Comparison of the Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease (SJIA-LD) Cohort to CARRA Registry SJIA Patients Without Lung Disease

    Esraa Eloseily1, Autumn Clark1, Min-Lee Chang2, Mary Ellen Riordan3, Alan Russell4, Marc Natter5, Scott Canna6, Sherry Thornton7, Yukiko Kimura8 and grant schulert1, and CARRA FROST Investigators and the CARRA Registry SJIA-LD Cohort Investigators, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, 3Hackensack University Medical Center, Westwood, NJ, 4Duke Clinical Research Institute, Durham, NC, 5Boston Children's Hospital, Boston, MA, 6Children's Hospital of Philadelphia, Philadelphia, PA, 7Cincinnati Children's Hospital, Cincinnati, 8Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging life-threatening disease with urgent unmet knowledge gaps. This study compares the clinical…
  • Abstract Number: L06 • ACR Convergence 2023

    Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)

    Kathryn Torok1, Paulina Horvei1, Franziska Rosser1, Kirsten Rose-felker2, Vibha Sood2, Adam Olsen2, Nicole Hogue2, Vickie Vandergrift2, Lauren Farver2, Devin Mcguire2, Jonathan Li3, Haley Havrilla2, Jessie Alexander4, Shawna McIntyre2 and Paul Szabolcs1, 1University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Stanford Children's Hospital, Palo Alto, CA

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
  • Abstract Number: 0354 • ACR Convergence 2023

    Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks

    Nicolino Ruperto1, Daniel J Lovell2, Sarah Ringold3, Xie L. Xu4, Jocelyn H. Leu3, Edwin Lam3, Yuhua Wang3, Alberto Martini5 and Hermine Brunner6, 1IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, 2UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, 3Janssen Research & Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC, San Diego, CA, 5Universita degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, 6Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH

    Background/Purpose: The phase 3, Intravenous Golimumab in Pediatric Participants with Active Polyarticular-Course JIA Despite MTX (GO-VIVA) study demonstrated that golimumab (GLM) 80 mg/m2 at Week…
  • Abstract Number: 0374 • ACR Convergence 2023

    Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry

    Bashayer Alnuaimi1, Michelle Batthish2, Roberta A Berard3, Gilles Boire4, Sarah Campillo1, Amieleena Chhabra5, Julie Couture6, Paul Dancey7, Brian Feldman8, Tommy Gerschman9, Julie Herrington10, Kristin Houghton11, Adam Huber12, Claire LeBlanc1, Lillian Lim13, Jean-Philippe Proulx-Gauthier6, Heinrike Schmeling14, Rosie Scuccimarri1, Lori Tucker15, Jaime Guzman15, Gaëlle Chédeville1 and For The CAPRI Registry Investigators16, 1McGill University Health Center, Montreal, QC, Canada, 2McMaster Children's Hospital, Hamilton, ON, Canada, 3Children's Hospital - London Health Sciences Centre, London, ON, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5British Columbia Hospital, Vancouver, BC, Canada, 6CHU de Quebec- Universite Laval, Quebec City, QC, Canada, 7Memorial University of Newfoundland, St. John's, NL, Canada, 8The Hospital for Sick Children, Toronto, ON, Canada, 9British Columbia Children's Hospital, Burnaby, BC, Canada, 10McMaster University, Hamilton, ON, Canada, 11British Columbia University, Vancouver, BC, Canada, 12IWK Health Centre, Halifax, NS, Canada, 13University of Alberta, Edmonton, AB, Canada, 14University of Calgary, Calgary, AB, Canada, 15British Columbia Children's Hospital, Vancouver, BC, Canada, 16CAPRI, Montreal, QC, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
  • Abstract Number: 1029 • ACR Convergence 2023

    Social Determinants of Health in Children with Rheumatic Disease: A Single Center Cohort

    Kristina Ciaglia1, Elizabeth Sloan1 and Tracey Wright2, 1UT Southwestern and Scottish Rite for Children, Dallas, TX, 2UT Southwestern, Dallas, TX

    Background/Purpose: Rheumatic disease disproportionately impacts certain socioeconomic, racial, and ethnic groups frequently resulting in health care inequities. Social determinants of health (SDOH) are conditions in…
  • Abstract Number: 1234 • ACR Convergence 2023

    Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity

    Jaqueline de amorim1, Simone Kishimoto1, Paula Fernandes1, Roberto Marini2, Zahi Touma3, Hermine Brunner4 and Simone Appenzeller1, 1UNICAMP, Campinas, Brazil, 2Revista Brasileira de Reumatologia, Campinas, Brazil, 3University of Toronto, Toronto, ON, Canada, 4Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH

    Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
  • Abstract Number: 1254 • ACR Convergence 2023

    Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)

    Amita Aggarwal1, Ranjan Gupta2, Liza Rajasekhar3, Ashish J Mathew4, Parasar Ghosh5, Chengappa Kavadichanda6, Vineeta Shobha7, Bidyut Das8, Manish Rathi9, Avinash Jain10 and Able Lawrence1, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 2All India Institute of Medical Sciences, New Delhi, India, 3Nizam's Institute of Medical Sciences, Madhapur, India, 4Christian Medical College, Vellore, India, 5Govt of West Bengal, Kolkata, India, 6Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 7St. John's National Academy of Health Science, Bangalore, India, 8SCB medical college, Cuttack, India, 9Postgraduate Institute of Medical education and Research, Chandigarh, India, 10SMS Medical College, Lucknow, India

    Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
  • Abstract Number: 1709 • ACR Convergence 2023

    Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction

    Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
  • Abstract Number: 2054 • ACR Convergence 2023

    Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience

    Ilaria Maccora1, Catherine Guly2, Lavinia Sanfilippo3, sara Soldovieri4, Cinzia De Libero5, Athimalaipet V Ramanan6 and Gabriele Simonini7, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2Ophthalmology Unit, Bristol Eye Hospital, Bristol, United Kingdom, 3Meyer Children's Hospital IRCCC, Florence, Italy, 4Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence, Italy, 5Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, 6Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, 7Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy

    Background/Purpose: Childhood Chronic Idiopathic Uveitis (cCIU) is a severe ocular condition that accounts for the 40% of all uveitis in children. Its timely and proper…
  • Abstract Number: 2589 • ACR Convergence 2023

    Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus

    Emily Zhang1, Sarah Capponi2, Rebecca Scobell3, Gabrielle Alonzi1, Madeline Hlobik1, Esra Meidan4, Mindy Lo4, Olha Halyabar5, Melissa Hazen1, Ezra Cohen6, Lauren Henderson1, Siobhan Case7, Margaret Chang1, Ankana Daga1, Jonathan Hausmann8, Ahmad Bakhsh1, Liyoung Kim1, Daniel Ibanez1, Holly Wobma4, Fatma Dedeoglu4, Robert Sundel1, Peter Nigrovic1, Karen Costenbader9, Mary Beth Son4 and Joyce Chang1, 1Boston Children's Hospital, Boston, MA, 2Hospital of the University of Pennsylvania, New Hope, PA, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Division of Immunology, Boston Children's Hospital, Boston, MA, 5Children's Hospital/Boston Medical Center, Newton, MA, 6Bmc, Needham, MA, 7Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, 8Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, 9Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Chronic glucocorticoid (GC) morbidity is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The pediatric glucocorticoid toxicity index (pGTI) (Brogan et…
  • Abstract Number: 0355 • ACR Convergence 2023

    Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis

    Ana Isabel Rebollo Gimenez1, Luca Carlini2, Paivi Miettunen3, Ekaterina Alexeeva4, Charlotte Myrup5, Rebecca Nicolai6, Maria Trachana7, Valda Stenevicha8, Constantin Ailioaie9, Elena Tsitsami10, Alexis-Virgil Cochino11, Chiara Pallotti12, Silvia Scala12, Angela Pistorio13, Sebastiaan Vastert14, Joost Swart15 and Nicolino Ruperto16, 1IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, 3University of Calgary and Alberta Children’s Hospital, Calgary, AB, Canada, 4Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 5Pediatric rheumatology unit 4272, Rigshospitalet, Copenhagen, Denmark, 6Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 7First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Thessaloniki University School of Medicine, Thessaloniki, Greece, 8Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, 9Pediatric Rheumatology , Alexandru Ioan Cuza University of Iasi, Iasi, Romania, 10Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, 11First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Childrens Hospital, Athens, Greece, 12Pediatric and Rheumatology Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 13Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 14University Medical Center Utrecht, Utrecht, Netherlands, 15Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, 16IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy

    Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology